Paratek reports positive data from Phase III trial of omadacycline

Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news